Verastem/$VSTM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Verastem
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Ticker
$VSTM
Sector
Primary listing
Employees
102
Headquarters
Website
Verastem Metrics
BasicAdvanced
$510m
-
-$2.41
0.34
-
Price and volume
Market cap
$510m
Beta
0.34
52-week high
$11.25
52-week low
$3.43
Average daily volume
2.9m
Financial strength
Current ratio
3.035
Quick ratio
2.874
Long term debt to equity
96.832
Total debt to equity
104.522
Interest coverage (TTM)
-128.65%
Profitability
EBITDA (TTM)
-169.855
Gross margin (TTM)
85.13%
Net profit margin (TTM)
-391.16%
Operating margin (TTM)
-344.56%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
-59.41%
Return on equity (TTM)
-786.15%
Valuation
Price to revenue (TTM)
9.397
Price to book
6.23
Price to tangible book (TTM)
7.76
Price to free cash flow (TTM)
-2.902
Free cash flow yield (TTM)
-34.46%
Free cash flow per share (TTM)
-1.999
Growth
Revenue change (TTM)
395.85%
Earnings per share change (TTM)
-31.00%
3-year earnings per share growth (CAGR)
-18.30%
10-year earnings per share growth (CAGR)
-17.54%
What the Analysts think about Verastem
Analyst ratings (Buy, Hold, Sell) for Verastem stock.
Verastem Financial Performance
Revenues and expenses
Verastem Earnings Performance
Company profitability
Verastem News
AllArticlesVideos
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
Business Wire·1 week ago
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·4 weeks ago
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.